Cancer is largely marked by genetic instability. Specific inhibition of individual proteins or signalling pathways that regulate genetic stability during cell division thus hold a great potential for cancer therapy. The Aurora A kinase is a Ser/Thr kinase that plays a critical role during mitosis and cytokinesis and is found upregulated in several cancer types. It is functionally regulated by its interactions with TPX2, a candidate oncogene. Aurora A inhibitors have been proposed as anticancer drugs that work by blocking its ATP binding site. This site is common to other kinases and hence these inhibitors lack specificity for Aurora A inhibition in particular, thus advocating the need of some alternative inhibition route. Previously, we identified TPX2 as a cellular target for withanone that selectively kill cancer cells. By computational approach, we found here that withanone binds to TPX2-Aurora A complex. In experiment, withanone treatment to cancer cells indeed resulted in dissociation of TPX2-Aurora A complex and disruption of mitotic spindle apparatus proposing this as a mechanism of the anticancer activity of withanone. From docking analysis, non-formation/disruption of the active TPX2-Aurora A association complex could be discerned. Our MD simulation results suggesting the thermodynamic and structural stability of TPX2-Aurora A in complex with withanone further substantiates the binding. We report a computational rationale of the ability of naturally occurring withanone to alter the kinase signalling pathway in an ATP-independent manner and experimental evidence in which withanone cause inactivation of the TPX2-Aurora A complex. The study demonstrated that TPX2-Aurora A complex is a target of withanone, a potential natural anticancer drug.
References
[1]
Karsenti E, Vernos I (2001) The mitotic spindle: a self-made machine. Science 294: 543–547.
[2]
Wittmann T, Boleti H, Antony C, Karsenti E, Vernos I (1998) Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. Journal of Cell Biology 143: 673–685.
[3]
Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nature Reviews Molecular Cell Biology 2: 21–32.
[4]
Bischoff JR, Plowman GD (1999) The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9: 454–459.
[5]
Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4: 842–854.
[6]
Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24: 5005–5015.
[7]
Andrews PD, Knatko E, Moore WJ, Swedlow JR (2003) Mitotic mechanics: the auroras come into view. Current Opinion in Cell Biology 15: 672–683.
[8]
Gruss OJ, Vernos I (2004) The mechanism of spindle assembly: functions of Ran and its target TPX2. Journal of Cell Biology 166: 949–955.
[9]
Eyers PA, Erikson E, Chen LG, Maller JL (2003) A novel mechanism for activation of the protein kinase Aurora A. Current Biology 13: 691–697.
[10]
Tsai MY, Wiese C, Cao K, Martin O, Donovan P, et al. (2003) A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nature Cell Biology 5: 242–248.
[11]
Bayliss R, Sardon T, Vernos I, Conti E (2003) Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 12: 851–862.
[12]
Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, et al. (2002) Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Research 62: 6803–6807.
[13]
Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, et al. (2005) Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 64: 341–346.
[14]
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, et al. (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clinical Cancer Research 9: 1420–1426.
[15]
Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S (2004) Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. International Journal of Oncology 25: 1631–1639.
[16]
Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, et al. (2004) Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncology Reports 12: 593–599.
[17]
Li Y, Li F, Li-Ling J, Wang X, Xu Z, et al. (2005) STK15 gene overexpression, centrosomal amplification, and chromosomal instability in the absence of STK15 mutations in laryngeal carcinoma. Cancer Investigation 23: 660–664.
[18]
Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, et al. (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clinical Cancer Research 9: 991–997.
[19]
Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, et al. (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Research 59: 2041–2044.
[20]
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, et al. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17: 3052–3065.
[21]
Zhang L, Huang H, Deng L, Chu M, Xu L, et al. (2008) TPX2 in malignantly transformed human bronchial epithelial cells by anti-benzo[a]pyrene-7,8-diol-9,10-epoxid？e. Toxicology 252: 49–55.
[22]
Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, et al. (2002) Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. Journal of Immunology 169: 1102–1109.
[23]
Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625–9630.
[24]
Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, et al. (2009) Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clinical Cancer Research 15: 6519–6528.
[25]
Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, et al. (2007) Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Research 67: 4390–4398.
[26]
Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, et al. (2007) The role of Aurora-A inhibitors in cancer therapy. Annals of Oncology 18: Suppl 6vi47–52.
[27]
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, et al. (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. Journal of Cell Biology 161: 281–294.
[28]
Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, et al. (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. The Journal of Cell Biology 161: 267–280.
[29]
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Medicine 10: 262–267.
[30]
Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G (2010) The Aurora-A/TPX2 complex: A novel oncogenic holoenzyme? Biochimica et Biophysica Acta 1806: 230–239.
[31]
Widodo N, Kaur K, Shrestha BG, Takagi Y, Ishii T, et al. (2007) Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clinical Cancer Research 13: 2298–2306.
[32]
Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, et al. (2008) Selective killing of cancer cells by leaf extract of Ashwagandha: Components, activity and pathway analyses. Cancer Letters 262: 37–47.
[33]
Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, et al. (2011) Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors. Biochem Biophys Res Commun 404: 498–503.
[34]
Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, et al. (2011) Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics 12: Suppl 1S30.
[35]
Grover A, Shandilya A, Bisaria VS, Sundar D (2010) Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes. BMC Genomics 11: Suppl 4S 15.
[36]
Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D (2010) Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A. BMC Genomics 11: Suppl 4S 25.
[37]
Widodo N, Priyandoko D, Shah N, Wadhwa R, Kaul SC (2010) Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling. PLoS One 5: e13536.
[38]
Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, et al. (1998) DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152: 1107–1123.
[39]
Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, et al. (2008) Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47: 755–765.
[40]
Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, et al. (2008) Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2. Protein Science 17: 1791–1797.
[41]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The protein data bank. Nucleic Acids Research 28: 235–242.
[42]
NCBI-PubChem Compound database.
[43]
Anderson K, Yang J, Koretke K, Nurse K, Calamari A, et al. (2007) Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 46: 10287–10295.
[44]
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19: 1639–1662.
[45]
Dym O, Xenarios I, Ke HM, Colicelli J (2002) Molecular docking of competitive phosphodiesterase inhibitors. Molecular Pharmacology 61: 20–25.
[46]
Rao MS, Olson AJ (1999) Modelling of Factor Xa-inhibitor complexes: A computational flexible docking approach. Proteins-Structure Function and Genetics 34: 173–183.
[47]
Goodsell DS, Morris GM, Olson AJ (1996) Automated docking of flexible ligands: Applications of AutoDock. Journal of Molecular Recognition 9: 1–5.
[48]
DeLano W (2002) The PyMOL Molecular Graphics System 2002. San Carlos, CA: DeLano Scientific.
[49]
Gupta A, Gandhimathi A, Sharma P, Jayaram B (2007) ParDOCK: An all atom energy based Monte Carlo docking protocol for protein-ligand complexes. Protein and Peptide Letters 14: 632–646.
[50]
Case DA DT, Cheatham TE, Simmerling CL, Wang J, Duke RE, et al. (2010) AMBER 11. San Francisco: University of California.
[51]
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 79: 926–935.
[52]
Bayly CI, Cieplak P, Cornell WD, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the resp model. Journal of Physical Chemistry 97: 10269–10280.
[53]
Cornell WD, Cieplak P, Bayly CI, Kollman PA (1993) Application of resp charges to calculate conformational energies, hydrogen-bond energies, and free-energies of solvation. Journal of the American Chemical Society 115: 9620–9631.
[54]
Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, et al. (1996) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. Journal of the American Chemical Society 118: 2309–2309.
[55]
Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. Journal of Chemical Physics 81: 3684–3690.
[56]
Kleywegt GJ, Jones TA (1996) Phi/psi-chology: Ramachandran revisited. Structure 4: 1395–1400.
